Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

NCT05463679 · clinicaltrials.gov ↗

PHASE3

Phase

SUSPENDED

Status

260

Enrollment

INDUSTRY

Sponsor class

Stopped Indefinite hold by company

Conditions

Vascular Ehlers-Danlos Syndrome

Interventions

DRUG: Enzastaurin
DRUG: Placebo

Sponsor

Aytu BioPharma, Inc.

Collaborators

[object Object]